ArticleOncoimmunology2022

The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.

Jiwei Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.